Angion Biomedica Corp. (ANGN)
Angion Biomedica Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Uniondale, NY, US. The stock last traded at $1.00, up 0.00% on the session, giving a market capitalisation of $30.1M. On trailing twelve-month figures it carries a trailing P/E of -0.47, a net margin of 0.0%. Its beta of 0.60 implies it has historically moved less than the broad market.
Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Angion Biomedica Corp. is most often compared with the following Healthcare names: